2024

Bourgonje AR, Visschedijk MC, Festen EAM, Weersma RK, Dijkstra G. Treatment strategies and biomarkers in Crohn’s disease: the PROFILE trial. Lancet Gastroenterol Hepatol 2024;9(7):590-591. doi: 10.1016/S2468-1253(24)00120-1.

Bourgonje AR, Geertsema S, Holstein HJ, Bulthuis MLC, Dijkstra G, Faber KN, van Goor H. Evaluating Serum Free Thiols in Inflammatory Bowel Disease: Contribution of Albumin to Extracellular Free Thiol Status. Inflamm Bowel Dis 2024; izae102. doi: 10.1093/ibd/izae102.

Barth I, Stevens CL, Strokap JC, Campmans-Kuijpers MJE, Bourgonje AR, Dijkstra G. Letter: Diet-microbiome interactions in inflammatory bowel disease-Navigating towards individualized dietary strategies. Aliment Pharmacol Ther 2024;59(9):1154-1155. doi: 10.1111/apt.17927.

Geertsema S, Fagundes RR, Otten AT, Dijkstra G, Faber KN, Bourgonje AR. Interleukin-18 Inhibition in Inflammatory Bowel Disease: A Delicate Balance. Inflamm Bowel Dis 2024;30(4):693-694. doi: 10.1093/ibd/izae042.

2023

Bourgonje AR, Mian P. Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Towards Personalized Evidence-Based Dosing Regimens. Am J Gastroenterol 2023;118(12):2308-2309. doi: 10.14309/ajg.0000000000002365.

Geertsema S, van Goor H, Dijkstra G, Faber KN, Bourgonje AR. Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases – moving towards causal associations. Aliment Pharmacol Ther 2023;57(9):1046-1047. doi: 10.1111/apt.17455.

Geertsema S, Otten AT, Bouwknegt DG, Visschedijk MC, Bourgonje AR. Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2023;29(3):e10-e11. doi: 10.1093/ibd/izac265.

Bourgonje AR, Otten AT. The Risk of Developing Long COVID in Patients with Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter? Clin Gastroenterol Hepatol 2023;21(7):1971-1972. doi: 10.1016/j.cgh.2022.12.030.

2022

Bourgonje AR. Microbial Riboflavin Biosynthesis Associates With Response to Dietary Fiber Consumption: Time to Personalize Adjunct Therapy in Patients With Inflammatory Bowel Disease? Gastroenterology 2023;165(2):515-516. doi: 10.1053/j.gastro.2022.10.016.

Bourgonje AR. Evaluating Discriminative Accuracy of Biomarkers in Relation to Binary Study Outcomes: First Validate, Then Celebrate? J Crohns Colitis 2023;17(1):146. doi: 10.1093/ecco-jcc/jjac117.